ADPKD may represent another cost-effective model if clinical evidence corroborates the putative therapeutic potential of IL-1 suppression suggested by experimental and genetic studies (99, 100, 126–128). The gene discussed is IL1A; the disease is autosomal dominant polycystic kidney disease.